news13 January 2020 | By Hannah Balfour (European Pharmaceutical Review)
The BEAT-MS trial aims to compare the experimental autologous hematopoietic stem cell transplantation (AHSCT) therapy to the best available biologic therapies for multiple sclerosis (MS).